Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 4/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | METAP1 | P53582 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL535632 | 0.85 | TRPA1 (0.37) | TRPA1HSD11B1MALT1TDP1TRPV1 | |
| SCHEMBL535573 | 0.83 | CDC25B (0.31) | TDP1 | |
| SCHEMBL535921 | 0.83 | HSD11B1 (0.41) | TRPA1HSD11B1MALT1TRPV1CYP17A1 | |
| SCHEMBL536188 | 0.83 | RPS6KA5 (0.31) | TDP1KDM4EMAPT | |
| SCHEMBL536083 | 0.83 | TRPA1 (0.34) | TRPA1HSD11B1MALT1TRPV1 | |
| SCHEMBL536183 | 0.83 | TRPA1 (0.34) | TRPA1HSD11B1MALT1TRPV1 | |
| SCHEMBL535335 | 0.83 | TRPV1 (0.35) | HSD11B1TRPV1KDM4ELMNAMAPT | |
| SCHEMBL535524 | 0.83 | TDP1 (0.31) | TDP1KDM4ELMNAHSP90AA1MAPT | |
| SCHEMBL535274 | 0.80 | HSD11B1 (0.33) | TRPA1HSD11B1TRPV1CYP17A1CYP1A2 | |
| SCHEMBL535494 | 0.80 | MALT1 (0.35) | MALT1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247431-B2 | Heterocyclic hydrazide compound and pesticidal use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-21 | — | — | US | disclosed |
| EP-2144898-B1 | HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | SUMITOMO CHEMICAL CO (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-7968573-B2 | Hydrazide compound and pesticidal use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-06-28 | — | — | US | disclosed |
| EP-1937664-B1 | HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | SUMITOMO CHEMICAL CO (JP) | 2011-06-15 | — | — | EP | disclosed |
| US-20110071291-A1 | HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | IKEGAMI HIROSHI | 2011-03-24 | — | — | US | disclosed |
| US-7867949-B2 | Hydrazide compound and pesticidal use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-01-11 | — | — | US | disclosed |
| EP-2251336-A1 | Hydrazide compounds as intermediates of pesticides | Sumitomo Chemical Company, Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
| US-20100137314-A1 | HARMFUL ORGANISM CONTROL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-03 | — | — | US | disclosed |
| US-20100137362-A1 | HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-03 | — | — | US | disclosed |
| US-20100099692-A1 | HARMFUL ORGANISM CONTROL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20090181956-A1 | Hydrazide Compound and Pesticidal Use of the Same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099692-A1 | HARMFUL ORGANISM CONTROL COMPOSITION | UQCRC1, UQCRC2, Q6ZSR9 | TRPA1 1072/4885HSD11B1 2805/4885MALT1 4850/4885 |
| US-20110071291-A1 | HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | ACHE, H1-2, H1-0 | TRPA1 437/4885HSD11B1 1797/4885MALT1 4856/4885 |
| US-20100137314-A1 | HARMFUL ORGANISM CONTROL COMPOSITION | UQCRC2, UQCRC1, UQCRB | TRPA1 1001/4885HSD11B1 2225/4885MALT1 4804/4885 |
| US-20090181956-A1 | Hydrazide Compound and Pesticidal Use of the Same | ACHE, DDT, CAT | TRPA1 359/4885HSD11B1 651/4885MALT1 4865/4885 |
| US-20100137362-A1 | HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | ACHE, CAT, DNPH1 | TRPA1 134/4885HSD11B1 584/4885MALT1 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.